Genascence Announces Six-Month Results From Phase 1b DONATELLO Trial Indicating GNSC-001 Was Safe and Well Tolerated Across Multiple Dosing Arms

UF startup Genascence Corporation, a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, announced positive interim safety and biomarker results from the Phase 1b DONATELLO clinical trial evaluating GNSC-001. GNSC-001 is an investigational AAV gene therapy product for knee osteoarthritis (OA) that encodes interleukin 1 receptor antagonist (IL-1Ra), a potent inhibitor of interleukin 1 (IL-1). Data from the six-month analysis demonstrated acceptable safety and tolerability across all doses tested, along with encouraging biomarker data.